Season 8 · Episode 39
S8 Ep39: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
OncLive® On Air · OncLive® On Air
April 24, 202318m 38s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating such an active combination regimen into the frontline setting for this population.